These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31331770)

  • 1. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.
    Kennedy EM; Dowall SD; Salguero FJ; Yeates P; Aram M; Hewson R
    Vaccine; 2019 Aug; 37(36):5404-5413. PubMed ID: 31331770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunisation of cattle against Babesia bovis combining a multi-epitope modified vaccinia Ankara virus and a recombinant protein induce strong Th1 cell responses but fails to trigger neutralising antibodies required for protection.
    Jaramillo Ortiz JM; Paoletta MS; Gravisaco MJ; López Arias LS; Montenegro VN; de la Fournière SAM; Valenzano MN; Guillemi EC; Valentini B; Echaide I; Farber MD; Wilkowsky SE
    Ticks Tick Borne Dis; 2019 Oct; 10(6):101270. PubMed ID: 31445874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
    Kou Y; Xu Y; Zhao Z; Liu J; Wu Y; You Q; Wang L; Gao F; Cai L; Jiang C
    Immunol Lett; 2017 Oct; 190():51-57. PubMed ID: 28728855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
    Flaxman A; Sebastian S; Appelberg S; Cha KM; Ulaszewska M; Purushotham J; Gilbride C; Sharpe H; Spencer AJ; Bibi S; Wright D; Schmidt I; Dowall S; Easterbrook L; Findlay-Wilson S; Gilbert S; Mirazimi A; Lambe T
    PLoS Pathog; 2024 Jun; 20(6):e1012262. PubMed ID: 38924060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model.
    Weidinger G; Ohlmann M; Schlereth B; Sutter G; Niewiesk S
    Vaccine; 2001 Apr; 19(20-22):2764-8. PubMed ID: 11282186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.
    Auperin DD; Esposito JJ; Lange JV; Bauer SP; Knight J; Sasso DR; McCormick JB
    Virus Res; 1988 Feb; 9(2-3):233-48. PubMed ID: 3354260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.